Related Experiment Videos
An anti-HIV peptide, T22, forms a highly active complex with Zn(II)
H Tamamura1, A Otaka, T Murakami
1Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
Biochemical and Biophysical Research Communications
|December 13, 1996
Summary
The peptide T22 shows significant anti-human immunodeficiency virus (HIV) activity. Complexing T22 with zinc ions (Zn(II)) further enhances its anti-HIV potency by fourfold, offering a promising therapeutic strategy.
Area of Science:
- Biochemistry
- Virology
- Medicinal Chemistry
Background:
- The peptide T22 exhibits potent anti-human immunodeficiency virus (HIV) activity, comparable to the antiviral drug AZT.
- T22 possesses an antiparallel beta-sheet structure stabilized by disulfide bonds and contains repeating Cys-Tyr-Arg-Lys-Cys sequences.
Purpose of the Study:
- To investigate the complexation of T22 with zinc ions (Zn(II)).
- To evaluate the impact of Zn(II) complexation on the anti-HIV activity of T22.
Main Methods:
- High-performance liquid chromatography (HPLC) was used to analyze the peptide.
- Ion spray mass spectrometry confirmed the formation of a T22-Zn(II) complex.
- The anti-HIV activity of T22 and its Zn(II) complex was assessed.
Main Results:
- Fully reduced T22 formed a stable 1:1 complex with Zn(II) at neutral pH in aqueous solution.
- Zn(II) complexation involved tetracoordinate bonding to the sulfur atoms of four cysteine residues.
- The T22-Zn(II) complex demonstrated a fourfold increase in anti-HIV activity compared to T22 alone.
Conclusions:
- T22 forms a well-defined complex with Zn(II) through its cysteine residues.
- Zinc complexation significantly potentiates the anti-HIV activity of T22.
- The T22-Zn(II) complex represents a potential new therapeutic agent for HIV treatment.